Zaks joins board at Teva
Jogerst named CBO at Rubius, plus updates from Telix, Talis, Ziopharm, Pyxis and more
Tal Zaks will become an independent director on the science and technology committee at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). His term will start Oct.1 and run until the annual shareholder meeting in 2022. As previously announced, Zaks, who has been CMO at Moderna Inc. (NASDAQ:MRNA) for the past six years, will leave the mRNA company in late September. He remains a special adviser to the CEO at Moderna.
Rubius Therapeutics Inc. (NASDAQ:RUBY) hired Jim Jogerst as CBO. Jogerst previously led licensing transactions for the infectious diseases and vaccines business of the Janssen Pharmaceuticals unit of Johnson & Johnson (NYSE:JNJ), where he was senior director of business development. Rubius is a clinical-stage biopharma developing off-the-shelf allogeneic cell therapies for several diseases, including cancer and autoimmune diseases...